科笛－Ｂ
Huanzhi Building
20th Floor 436 Heng Feng Road Jingan District
Shanghai 200070
China
86 21 5298 2688
https://www.cutiatx.com
版塊: Healthcare
行業: Biotechnology
全職員工: 298
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Ms. Lele Zhang | Founder, CEO & Executive Director | 4.58M | 無 | 1977 |
| Mr. Yuqing Huang | CFO & Executive Director | 7.71M | 無 | 1990 |
| Mr. Qi Zhu | Chief Medical Officer | 無 | 無 | 1973 |
| Dr. Lei Lei | Senior Vice President of Research & Development Department | 無 | 無 | 1985 |
| Ms. Chunna Zhang | Senior Vice President of Regulatory Affairs Department | 無 | 無 | 1979 |
| Ms. Jingxin Xu | Senior Vice President of Manufacturing & Quality Control Department | 無 | 無 | 1979 |
| Mr. Jiaru Wu | Senior Vice President of Finance & Integrated Management Department | 無 | 無 | 1984 |
| Ms. Sze Ting Chan A.C.S. | Company Secretary | 無 | 無 | 1982 |
描述
Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People's Republic of China and Hong Kong. It focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company's products include CU-40102, a topical finasteride spray approved for androgenetic alopecia treatment; CU-10201, a topical 4% minocycline foam, approved for acne vulgaris treatment; and CU-10101, a topical novel small molecule agent, and a non-hormonal and small molecule drug for the treatment of mild to moderate atopic dermatitis. It is also involved in the development of CU-20401, a recombinant mutant collagenase, currently under Phase II clinical trial for submental adipose accumulation (submental fat); CU-40101, a topical small molecule thyroid hormone receptor agonist liniment, currently completed Phase I clinical trial for the treatment of androgenetic alopecia; and CU-30101, a localized topical lidocaine and tetracaine compound topical anesthesia cream, completed Phase III clinical trial for surface dermatologic operations. The company was incorporated in 2019 and is headquartered in Shanghai, China.
公司管治
截至 無 止，科笛－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
